3 promises healthcare AI will almost surely keep

AI continues to wow healthcare watchers with sharp guidance on clinical decisionmaking, accurate aids to risk assessment and bankable workflow efficiencies. But healthcare was, is and always will be about “human-to-human relationships, trust and healing.”

So maintains Stevin Lin, MD, Stanford Medicine’s vice chief for technology innovation in primary care and population health.

Lin takes questions from Stanford’s news division in a Q&A session posted online May 28. Along the way, he suggests numerous pathways along which AI is likely to revitalize healthcare without displacing healthcare workers.

Here are three:

1. AI will boost physicians’ wellness and job satisfaction. “Automating repetitive tasks that are suffocating physicians and their practices is one of the most anticipated applications of AI,” Lin says.

2. AI won’t just improve patient care—it will also help ensure optimal outcomes. “In many regions of the world that lack access to specialty care,” Lin notes, “AI-powered tools in the hands of primary care physicians could provide significant, if not lifesaving, benefits to patients.”

3. AI will help cut unnecessary healthcare spending. “In the United States, hospital costs for potentially preventable conditions account for 1 in every 10 dollars of total hospital expenditures,” Lin says. “This means that millions of hospital stays and up to $100 billion a year might be prevented with better risk prediction and interventions in the primary care setting with AI.”

Read the whole Q&A from which these points were drawn:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.